Published in Cancer Res on July 01, 2001
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet (2002) 3.00
The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev (2009) 2.56
miR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat Struct Mol Biol (2009) 2.54
G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer (2008) 2.33
Human Tousled like kinases are targeted by an ATM- and Chk1-dependent DNA damage checkpoint. EMBO J (2003) 1.67
ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol (2014) 1.35
Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer (2009) 1.33
Differentiation-induced radioresistance in muscle cells. Mol Cell Biol (2004) 1.30
Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. J Clin Invest (2010) 1.13
Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle (2010) 1.11
Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease. Hum Mol Genet (2010) 1.01
Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379. Mol Cell Biol (2008) 0.98
Activation of checkpoint kinase 2 by 3,3'-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells. Mol Pharmacol (2010) 0.95
DNA damage response by single-strand breaks in terminally differentiated muscle cells and the control of muscle integrity. Cell Death Differ (2012) 0.90
The DNA damage response induced by infection with human cytomegalovirus and other viruses. Viruses (2014) 0.90
The E3 ligase PIRH2 polyubiquitylates CHK2 and regulates its turnover. Cell Death Differ (2013) 0.87
Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors. Oncogene (2014) 0.87
Mahanine, a novel mitochondrial complex-III inhibitor induces G0/G1 arrest through redox alteration-mediated DNA damage response and regresses glioblastoma multiforme. Am J Cancer Res (2014) 0.87
Expression of activated checkpoint kinase 2 and histone 2AX in exfoliative oral cells after exposure to ionizing radiation. Radiat Res (2009) 0.85
Genetic and epigenetic features in radiation sensitivity Part I: cell signalling in radiation response. Eur J Nucl Med Mol Imaging (2005) 0.84
Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia. BMC Cancer (2012) 0.83
Alterations of Chk1 and Chk2 expression in colon cancer. Int J Colorectal Dis (2008) 0.77
Glucose deprivation is associated with Chk1 degradation through the ubiquitin-proteasome pathway and effective checkpoint response to replication blocks. Biochim Biophys Acta (2011) 0.77
Global analysis of phosphorylation of tau by the checkpoint kinases Chk1 and Chk2 in vitro. J Proteome Res (2013) 0.77
The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis. Br J Cancer (2004) 0.77
CHK2 stability is regulated by the E3 ubiquitin ligase SIAH2. Oncogene (2016) 0.76
Oxoaporphine Metal Complexes (Co(II), Ni(II), Zn(II)) with High Antitumor Activity by Inducing Mitochondria-Mediated Apoptosis and S-phase Arrest in HepG2. Sci Rep (2017) 0.75
Checkpoint kinase Chk2 controls renal Cyp27b1 expression, calcitriol formation, and calcium-phosphate metabolism. Pflugers Arch (2014) 0.75
Curcumin induces G2/M cell cycle arrest and apoptosis of head and neck squamous cell carcinoma in vitro and in vivo through ATM/Chk2/p53-dependent pathway. Oncotarget (2017) 0.75
Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev (1993) 8.03
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature (2001) 6.73
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (1995) 4.78
Rapid destruction of human Cdc25A in response to DNA damage. Science (2000) 4.74
Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet (1990) 4.49
Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol (2001) 4.22
Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A. Nat Cell Biol (1999) 3.74
DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene (2007) 3.67
Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res (1994) 3.65
Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J (1999) 3.41
High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res (1996) 3.18
Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol (1995) 3.16
Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its subcellular localization. EMBO J (1999) 3.05
Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev (1997) 3.02
Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci (1994) 3.00
Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts. J Cell Biol (1993) 2.83
Cyclin D1 protein expression and function in human breast cancer. Int J Cancer (1994) 2.81
Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol (2001) 2.77
CHK2 kinase--a busy messenger. Nat Rev Mol Cell Biol (2001) 2.68
Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature (1999) 2.63
Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut (1996) 2.63
Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim (1995) 2.63
Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2001) 2.59
Pathways governing G1/S transition and their response to DNA damage. FEBS Lett (2001) 2.58
Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression. Mol Cell Biol (1996) 2.44
Induction of S-phase entry by E2F transcription factors depends on their nuclear localization. Mol Cell Biol (1997) 2.27
DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol (1994) 2.11
Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene (1994) 2.10
Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci U S A (1994) 2.09
Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). J Cell Biol (1994) 2.08
Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: relation to in vivo phenotypes and influence of medium. J Cell Sci (1989) 2.07
Diagnostic reliability of histological and cytological fine needle biopsies from focal liver lesions. Histopathology (1989) 2.00
Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J (1995) 1.92
The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol (1996) 1.87
Factor VII related antigen as an endothelial cell marker in benign and malignant diseases. Virchows Arch A Pathol Anat Histol (1981) 1.78
Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol (1996) 1.75
Nonperiodic activity of the human anaphase-promoting complex-Cdh1 ubiquitin ligase results in continuous DNA synthesis uncoupled from mitosis. Mol Cell Biol (2000) 1.74
Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem (2004) 1.74
Seroprevalence of tetanus antibodies among adults older than 65 years. Ann Emerg Med (1996) 1.71
The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer (1994) 1.71
Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res (1995) 1.68
Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus. Proc Natl Acad Sci U S A (1991) 1.63
The CHEK2 gene and inherited breast cancer susceptibility. Oncogene (2006) 1.62
Substrate specificity and cell cycle regulation of the Nek2 protein kinase, a potential human homolog of the mitotic regulator NIMA of Aspergillus nidulans. J Biol Chem (1995) 1.61
Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia (2004) 1.59
Patterns of expression of keratin 19 as detected with monoclonal antibodies in human breast tissues and tumours. Int J Cancer (1985) 1.57
The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res (1996) 1.55
'Blind' antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. Ann Oncol (2006) 1.54
Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease--a population-based study. Aliment Pharmacol Ther (2011) 1.53
A conserved cyclin-binding domain determines functional interplay between anaphase-promoting complex-Cdh1 and cyclin A-Cdk2 during cell cycle progression. Mol Cell Biol (2001) 1.53
Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene (1998) 1.52
Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene (2010) 1.52
Intracranial Pressure Monitoring: Invasive versus Non-Invasive Methods-A Review. Crit Care Res Pract (2012) 1.51
Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts. J Biol Chem (1996) 1.50
SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia (2013) 1.50
Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett (1995) 1.48
Modulation of cyclin gene expression by adenovirus E1A in a cell line with E1A-dependent conditional proliferation. J Virol (1994) 1.46
A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer (1989) 1.46
Hemodynamic effect of carotid endarterectomy. Stroke (1987) 1.45
Activation of peroxisome proliferator-activated receptor gamma bypasses the function of the retinoblastoma protein in adipocyte differentiation. J Biol Chem (1999) 1.44
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis. Oncogene (1999) 1.42
Are self-expanding stents superior to balloon-expanded in dilating aortas? An experimental study in pigs. Eur J Vasc Endovasc Surg (1996) 1.40
Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol (2001) 1.40
DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene (2007) 1.40
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia (2013) 1.39
The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene (2007) 1.39
Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene (1995) 1.39